It is a moment of great excitement for AEterna Zentaris Inc (NASDAQ:AEZS). This is after the giant company received the much anticipated report from the U.S. Food and Drug Administration (“FDA”).It received the news today and it is happy that its New Drug Application (“NDA”) has gone through the most challenging stage.
The U.S. Food and Drug Administration has taken quite some time to evaluate the product to find out if it aligns to their set criteria. After discovering it to be an idea product that will help people globally, it decided to let it pass and now it is ready for the global market. The growth hormone deficiency among adults is an area already conquered and people from around the globe are waiting to experience the new medication according to Yahoo.
This top American body gave its approval through a Complete Response Letter which the company received on November 5, 2014.
The President and Chief Executive Officer of the Company, David A. Dodd, in the board meeting said, “We are pleased that the FDA has formally accepted our resubmitted NDA and that it is under active review with an end-of-year PDUFA date. We remain confident that the FDA will approve our NDA and, therefore, we are moving forward with our preparations to launch the product in the first quarter of 2018.”
AEterna Zentaris Inc has also made the announcement that it will no longer be having Mr. Kenneth Newport serve it its Board of Directors. As it usually is the case during such instances for any top provider, a lot of speculation has cropped up. Some people are speaking negatively citing that the board member did not act with decorum in his last days with the company.
Everyone is of course entitled to his or her opinion. But the one point that holds water is the fact that the company hasn’t yet given its official report behind the dismissal of the top company executive. However, one thing that is for sure is the fact that most of the things the company does are for the general good. The company’s future looks bright especially after the recent success.